Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion
Thoracic oncologists previously touted Hyrnuo’s potential in HER2-mutant NSCLC in both the first- and second-line settings.
Therapy Area
ESC 2026: Tirzepatide 5mg sustains cardiometabolic benefit with weight maintenance
ESC 2026: Evidence supporting SGLT2 inhibitors and finerenone in heart failure grows
ESC 2026: Aficamten breaks new ground in nonobstructive HCM
ESC 2026: Evolocumab explores new frontiers in CV disease prevention
RevMed’s pancreatic cancer drug breezes through with swift approval
Johnson & Johnson’s multiple myeloma treatment secures EC approval
Intismeran autogene a turning point for cancer vaccines
